• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Kids v Cancer

Changing the landscape of pediatric research

DONATE
  • Who We Are
    • About Us
    • About Jacob
    • Mission and Impact
    • Press Kit
    • Contact
  • Policy Development
    • RACE for Children Act / PREA
    • Creating Hope Act / Pediatric Priority Review Vouchers
    • Kids’ Eligibility for Trials
  • For Doctors & Families
    • COMPASSIONATE USE NAVIGATOR
    • Brain Tissue Donation
  • News & publications
    • News
    • Pediatric Cancer Legislative Yearbook 2021
    • Pediatric Cancer Research Consortia 2019
    • Kids v Cancer End of Year Letter 2017
    • Blog
  • Youth Programs
    • All programs
    • Climb the Hill Youth Advocacy Day Sign Up
    • Video and photo gallery
    • Kids v Cancer Youth Board
  • Our stories
  • Get involved
    • Donate
    • Our Parent Council
    • Happy Day Gift
    • Become a Corporate Partner

Physician perspectives on compassionate use in pediatric oncology (Pediatric Blood & Cancer)

November 8, 2018

Full text

Scott Moerdler, Lindy Zhang, Elena Gerasimov, Chong Zhu, Tamar Wolinsky, Michael Roth, Nancy Goodman, Daniel A. Weiser
First published: 08 November 2018
Pediatr Blood Cancer. 2018 Nov 8:e27545.
https://doi.org/10.1002/pbc.27545

SM and LZ share first authorship of this article.

Abstract

1 Background

Targeted cancer treatments are almost always first studied in adults, even when there is a biologically plausible potential for efficacy in children. Through compassionate use programs, children who are not eligible for a clinical trial and for whom there are no known effective therapies may obtain access to investigational agents, including drugs under development for adults. However, little is known about pediatric oncologists’ experiences with applying for and obtaining compassionate use agents.

2 Methods

This study surveyed 132 pediatric oncologists to assess awareness and utilization of compassionate use programs, to identify barriers to their use, and to evaluate available institutional support and resources.

3 Results

We found that the process of applying for access to drugs in development is poorly understood, which presents a barrier to obtaining investigational drugs. Fifty‐seven percent of the pediatric oncologists applied for compassionate use. Providers from larger institutions or with more than 15 years of clinical experience were more likely to complete an application and obtain investigational agents for their patients.

4 Conclusion

Identified perceived and actual barriers to compassionate use application submission suggest pediatric oncologists may benefit from educational resources and support to ensure children with cancer equal access to investigational agents and care.

  • We are in the news
  • Our Publications
  • Our Newsletters
  • Our Op-Eds & Speeches
  • Legislation / Proclamations
  • Videos / Photos
  • RELEVANT NEWS
    • RACE for Children Act
    • Creating Hope Act / Pediatric priority review vouchers
    • Compassionate Use
    • Kids’ eligibility for trials
  • Facebook
  • Twitter

DONATE CONFLICT OF INTEREST SUBSCRIBE

Kids v Cancer · 3500 Macomb Street NW · Washington D.C. 20016 · 646-361-3590 · contact

© 2021 Kids v Cancer All Rights Reserved a 501(c)(3) nonprofit organization EIN 27-1427784 Privacy Policy Terms of Use Sitemap